INCY Incyte Corporation

Virginia Retirement Systems increased its stake in Incyte Corporation by 4.5% to 768,325 shares, valued at $65.16 million, as institutional ownership of the stock reached 96.97%. While analysts have a "Hold" consensus with an average target of $99.79, Q3 earnings surpassed expectations by a significant margin. However, insiders have recently sold approximately 88,318 shares worth about $8.7 million.

Incyte (Nasdaq: INCY) is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. This presentation is a significant event for investors, who will be closely observing developments in the company's oncology and inflammation and autoimmunity pipeline. The conference serves as a key forum for biopharmaceutical companies to outline clinical progress and strategic priorities.

The European Commission has approved Incyte's (Nasdaq: INCY) Minjuvi (tafasitamab) for use in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma. This approval introduces the first CD19- and CD20-dual-targeted, chemotherapy-free immunotherapy regimen for this patient population in Europe, providing a new option for patients with limited treatment choices. The decision was based on the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival for patients receiving the Minjuvi combination.

Burney Co. recently purchased 22,200 shares of Incyte Corporation (NASDAQ:INCY) in Q3, valued at approximately $1.883 million, contributing to institutional investors owning 96.97% of the stock. Meanwhile, insiders sold 88,318 shares totalling $8.71 million over the last quarter. Analysts currently maintain a "Hold" rating with an average target price of $99.79 for Incyte, which recently exceeded EPS and revenue estimates.

Cwm LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 49.8% in Q3, acquiring 65,292 shares to hold a total of 196,472 shares valued at approximately $16.66 million. Incyte recently outperformed earnings expectations, reporting an EPS of $2.26 against an anticipated $1.65, and revenues of $1.37 billion. Despite a consensus "Hold" rating from analysts, several firms have raised their price targets for the biopharmaceutical company.

The Vitiligo Drugs Market is projected to experience substantial growth from 2025 to 2032, driven by rising demand, technological advancements, and expanding applications. The report provides a comprehensive analysis of market size, revenue trends, key growth factors, and competitive landscape, offering actionable insights for strategic decision-making. Leading companies in this market include Dermavant Sciences Inc., Incyte Corporation, and Pfizer Inc.